Tejas Patil, MD, observes how groundbreaking data presented at ASCO 2024 is shaping the management of patients with advanced NSCLC. For ALK-rearranged NSCLC, the CROWN trial supports lorlatinib as the preferred first-line ALK inhibitor, highlighting its superior intracranial efficacy and low discontinuation rates. In limited-stage SCLC, the ADRIATIC trial indicates a shift toward using durvalumab post-chemoradiotherapy as the new standard of care, replacing traditional observation methods. Similarly, the LAURA trial establishes osimertinib as the standard for patients with EGFR-mutant NSCLC in stage IIIB, superseding prior approaches of chemoradiation or observation.
Moreover, for patients with EGFR-mutant NSCLC and leptomeningeal disease, the BLOSSOM study suggests maintaining the 80 mg dose of osimertinib, challenging previous practices of dose escalation to 160 mg. These findings signal a transformative era in lung cancer treatment, prioritizing personalized approaches to optimize patient outcomes.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: The Impact of ASCO 2024: Four Key Clinical Scenarios in Advanced NSCLC - Medscape - Jun 25, 2024.
Comments